Jerry Wisler President & CEO, Board Member, Co-Founder

Jerry Wisler has been in the pharmaceutical industry for over 25 years, serving in executive positions at Merck and Novartis, and as Co-Founder and President, CEO and Board Member of Aegerion Pharmaceuticals, Inc.


His career has been marked by successfully developing commercial brands, strategic excellence, leadership, innovation, and a deep scientific understanding. At Merck, his responsibilities included Timoptic®, Pepcid®, Prinivil®, Plendil®, and Zocor®. He was VP of Marketing at Merck, with responsibility for the atherosclerosis franchise. While responsible for Zocor® it grew from $1.8 billion in annual sales in 1997 to $5.3 billion in sales in 2002. Jerry was also involved in various lifecycle management activities for Zocor®, including an important role providing commercial input into the decision to enter into a Joint Venture with Schering-Plough for Zetia® and Vytorin®. At Novartis, Jerry served as VP of Marketing and was responsible for Diovan®, Lotrel®, and Starlix® and was actively involved in strategic initiatives and managed care contracting for the key brands.


Jerry also has extensive experience with managed care, with several important assignments in managed care at Merck, including VP of Managed Care marketing and contracting.

Michael H. Davidson, M.D. Chief Medical Officer, Co-Founder

Michael H. Davidson, M.D. is a Co-Founder of Omthera Pharmaceuticals and is serving as our Chief Medical Officer. Dr. Davidson is also a Clinical Professor at the University of Chicago, where he also serves as Director of Preventive Cardiology.


Dr. Davidson earned his medical degree from The Ohio State University College of Medicine in Columbus. He then fulfilled his residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center in Chicago, where he later completed a fellowship in cardiology. Dr. Davidson was the Founder, President, and Chief Executive Officer of the Chicago Center for Clinical Research, currently part of Radiant Research.


An active researcher, Dr. Davidson's clinical research background encompasses both pharmaceutical and nutritional clinical trials. His extensive research on statins, novel lipid-lowering drugs, and nonpharmacologic risk factor reduction has established him as a key opinion leader in this area. His research also includes extensive work with food additives, dietary supplements, and health claim petitions to the US Food and Drug Administration. A prolific author and lecturer on lipid disorders, nutrition, and atherosclerosis, Dr. Davidson has coordinated more than 700 clinical trials in areas of preventive cardiology and published more than 200 articles for leading medical journals.


Dr. Davidson is board-certified in internal medicine, cardiology, and clinical lipidology. He is a Fellow of the American College of Cardiology and the American College of Chest Physicians. In addition, he served as President of the Midwest Lipid Association and is a Board Member of the National Lipid Association. He was listed in America's Top Physicians by the Consumers' Research Council of America, 2004-2005, and named three times in The Best Doctors in America.

Christian S. Schade Executive Vice President and Chief Financial Officer

Mr. Schade brings to Omthera extensive experience as a public company financial executive in the biopharmaceutical and energy industries, as well as expertise in the public capital markets through his tenure in the investment banking industry.


Prior to joining Omthera in September 2011, from April 2010 through August 2011, Mr. Schade served as EVP and Chief Financial Officer at NRG Energy, a NYSE listed, S&P 500 wholesale power generation company. Before that, he was Senior Vice President Administration and Chief Financial Officer at Nasdaq-listed Medarex Inc., a leading pharmaceutical development company, where he helped to raise capital through a series of public capital market and asset monetization transactions, oversaw the manufacturing of multiple development/clinical programs, directed the business development team in the pursuit of key licensing agreements and potential acquisition opportunities, and spearheaded Medarex’s investor relations outreach. Mr. Schade also played a lead role in the negotiations for the sale of Medarex to Bristol-Myers Squibb Co. in September 2009, which was completed for $2.4 billion.


Before joining Medarex, Mr. Schade served as Managing Director at Merrill Lynch in London, where he was head of the European Corporate Funding Group. He also held various corporate finance and capital markets positions in New York and London for both Merrill Lynch and JP Morgan Chase & Co. Mr. Schade received an A.B. degree from Princeton University, and an M.B.A. from the Wharton School at the Universityof Pennsylvania. He currently serves on the Board of Directors at Integra Life Sciences (Nasdaq: IART).

Drs. Ben Machielse Chief Operating Officer

During his professional career, Drs. Machielse has been involved with the development and approval of seven biologic drugs. Prior to joining Omthera, he spent 11 years with MedImmune, the last five as Executive Vice President Operations. In that role, he led the worldwide manufacturing of therapeutic antibodies, small molecules and vaccine products - including the development and launch of the first H1N1 vaccine product available in the U.S. He also oversaw quality assurance/quality control, GxP compliance, validation, supply chain, health and safety, and other functional areas. Prior to his tenure with MedImmune, Drs. Machielse held the position of Vice President of Quality Assurance and Quality Control for Xoma, and before that, served in various positions in manufacturing, process and analytical development for Centocor BV. Drs. Machielse received his Master of Science in biochemistry and Bachelor of Science in Medical Biology from the University of Utrecht, in Utrecht, The Netherlands. He is a former member of the Board of Directors of Xencor and a current member of the Board of Directors for Tetragenetics.

Douglas Carr Financial Controller

As Financial Controller, Doug brings over 20 years of broad-based finance experience supporting US and international business operations. Prior to joining Omthera in November 2009, Doug was Controller - Pediatric Vaccines Franchise for Merck & Co., Inc., where he provided a full range of financial services for senior franchise leaders. He directed the financial planning and reporting processes and provided decision-support analysis on projects and initiatives. Doug was also Business Director for the Zocor franchise where he was responsible for day-to-day operations management of the ZOCOR Franchise (over $6 billion in sales), including forecasting, reporting, budget management and product/sample supply.


Doug is licensed as a Certified Public Accountant in New Jersey, and he received his B.A. degree in Accounting from Rutger's University.